Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study
| Autor: | Omid Hamid, Shweta Shah, David Cohan, Leon Raskin, Morganna Freeman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty BRAF/MEK inhibitors Immune checkpoint inhibitors retrospective study Dermatology medicine.disease_cause Systemic therapy 03 medical and health sciences 0302 clinical medicine Electronic records Internal medicine medicine melanoma neoplasms Advanced melanoma Mutation business.industry Melanoma Retrospective cohort study medicine.disease digestive system diseases BRAF status 030104 developmental biology treatment patterns 030220 oncology & carcinogenesis business checkpoint inhibitors Methods treatment Research Article |
| Zdroj: | Melanoma Management |
| ISSN: | 2045-0893 2045-0885 |
| Popis: | Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status. Patients & methods: Treatment patterns were evaluated in adults from the Oncology Services Comprehensive Electronic Records database who received antimelanoma systemic therapy. Results: Checkpoint inhibitors were prevailingly prescribed (66%); usage increased from 2011 (21%) to 2017 (84%). BRAF/MEK inhibitors were the second most common (21%); usage increased from 2011 (6%) to 2012 (18%) and stabilized until 2017 (22%). BRAF/MEK inhibitors (65%) and checkpoint inhibitors (57%) were predominantly used for BRAFMut melanoma. Conclusion: Overall, checkpoint inhibitors have supplanted other therapies for advanced melanoma. Treatment shifts have occurred for BRAFMut melanoma, notably increased use of checkpoint inhibitors and BRAF/MEK combinations compared with monotherapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|